ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.43 and traded as high as $6.76. ImmuCell shares last traded at $6.39, with a volume of 3,325 shares traded.
ImmuCell Stock Performance
The firm's 50 day moving average is $6.07 and its 200 day moving average is $5.45. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.21 and a current ratio of 4.12. The stock has a market cap of $60.70 million, a P/E ratio of -95.91 and a beta of 0.32.
ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%. The business had revenue of $8.07 million for the quarter.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Mesirow Financial Investment Management Inc. boosted its position in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after buying an additional 12,178 shares during the last quarter. Geode Capital Management LLC lifted its stake in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares during the period. Dauntless Investment Group LLC purchased a new stake in shares of ImmuCell in the 4th quarter valued at $676,000. Northern Trust Corp increased its stake in shares of ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of ImmuCell in the fourth quarter worth $149,000. 13.47% of the stock is currently owned by hedge funds and other institutional investors.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Recommended Stories
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
